Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 4/20 | 0.44 |
| ▸ | BTK | Q06187 | 11/20 | 0.42 |
| ▸ | FGFR2 | P21802 | 6/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | ITK | Q08881 | 1/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26587446 | 0.91 | FGFR2 (0.50) | FGFR4BTKFGFR2FGFR1ITK | |
| SCHEMBL30582518 | 0.91 | ITK (0.40) | FGFR4BTKFGFR2FGFR1ITK | |
| SCHEMBL26587541 | 0.89 | FGFR1 (0.47) | FGFR4BTKFGFR2FGFR1EGFR | |
| SCHEMBL26587732 | 0.88 | BTK (0.44) | FGFR4BTKFGFR2FGFR1EGFR | |
| SCHEMBL30582647 | 0.88 | SRC (0.41) | BTKEGFR | |
| SCHEMBL26587296 | 0.88 | BTK (0.47) | FGFR4BTKFGFR2FGFR1EGFR | |
| SCHEMBL26108267 | 0.88 | SRC (0.41) | BTKEGFR | |
| SCHEMBL30582517 | 0.86 | FGFR1 (0.46) | FGFR4BTKFGFR2FGFR1FGFR3 | |
| SCHEMBL30582526 | 0.85 | JAK3 (0.49) | FGFR4BTKFGFR2FGFR1EGFR | |
| SCHEMBL26133571 | 0.85 | JAK3 (0.49) | FGFR4BTKFGFR2FGFR1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4499616-A1 | SPIROBICYCLIC COMPOUNDS | Acerand Therapeutics (Hong Kong) Limited (HK) | 2025-02-05 | — | — | EP | claimed |
| CN-119013260-A | Spirobicyclic compounds | 优领医药科技(香港)有限公司 | 2024-11-22 | — | — | CN | claimed |
| WO-2023192502-A1 | SPIROBICYCLIC COMPOUNDS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2023-10-05 | — | — | WO | claimed |
| EP-4499616-A1 | SPIROBICYCLIC COMPOUNDS | Acerand Therapeutics (Hong Kong) Limited (HK) | 2025-02-05 | — | — | EP | disclosed |
| CN-119013260-A | Spirobicyclic compounds | 优领医药科技(香港)有限公司 | 2024-11-22 | — | — | CN | disclosed |
| WO-2023192502-A1 | SPIROBICYCLIC COMPOUNDS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023192502-A1 | SPIROBICYCLIC COMPOUNDS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2023-10-05 | — | — | WO | disclosed |